Skip to main content

Table 2 Characteristics of study CHCs’ patients with diabetes as of May 30, 2014 (beginning of pre-intervention period)

From: Does increased implementation support improve community clinics’ guideline-concordant care? Results of a mixed methods, pragmatic comparative effectiveness trial

  Arm 1 CHCs Arm 2 CHCs Arm 3 CHCs Comparison CHCs p value
N (%) N (%) N (%) N (%)
Total patients 3849   5098   3370   33,638
 Indicated for statin use 3299 (85.7) 4239 (83.2) 2850 (84.6) 28,257 (84.0) 0.009
 Indicated for ACE/ARB use 2589 (67.3) 3580 (70.2) 2369 (70.3) 22,808 (67.8) < 0.001
Age (years) 0.009
 18–21 31 (0.8) 33 (0.6) 24 (0.7) 212 (0.6)
 22 to 39 357 (9.3) 574 (11.3) 337 (10.0) 3649 (10.8)
 40 to 75 3169 (82.3) 4064 (79.7) 2744 (81.4) 27,309 (81.2)
 > 75 292 (7.6) 427 (8.4) 265 (7.9) 2468 (7.3)
Gender < 0.001
 Female 2047 (53.2) 3057 (60.0) 1831 (54.3) 18,707 (55.6)
 Male 1802 (46.8) 2041 (40.0) 1539 (45.7) 14,931 (44.4)
Race/ethnicity < 0.001
 Non-Hispanic White 2,417 (62.8) 880 (17.3) 2389 (70.9) 15,582 (46.3)
 Non-Hispanic Black 44 (1.1) 1364 (26.8) 196 (5.8) 7056 (21.0)
 Non-Hispanic Other 127 (3.3) 350 (6.9) 126 (3.7) 2134 (6.3)
 Hispanic 1249 (32.4) 2494 (48.9) 652 (19.3) 8734 (26.0)
 Unknown 12 (0.3) 10 (0.2) 7 (0.2) 132 (0.4)
Patient preferred language < 0.001
 English 2781 (72.3) 3259 (63.9) 2883 (85.5) 23,979 (71.3)
 Spanish 993 (25.8) 1690 (33.2) 395 (11.7) 7011 (20.8)
 Other 46 (1.2) 138 (2.7) 79 (2.3) 2372 (7.1)
 Unknown 29 (0.8) 11 (0.2) 13 (0.4) 276 (0.8)
Household income as % of FPL* < 0.001
 0 to 100% 1829 (47.5) 1456 (28.6) 1317 (39.1) 17,999 (53.5)
 101 to 200% 776 (20.2) 425 (8.3) 758 (22.5) 6393 (19.0)
 > 200% 122 (3.2) 62 (1.2) 287 (8.5) 2271 (6.8)
 Unknown 1122 (29.2) 3155 (61.9) 1008 (29.9) 6975 (20.7)
Insurance status* < 0.001
 Medicaid 1421 (36.9) 1924 (37.7) 1089 (32.3) 11,436 (34.0)  
 Medicare 1403 (36.5) 1725 (33.8) 1315 (39.0) 10,386 (30.9)  
 Other public 41 (1.1) 8 (0.2) 23 (0.7) 742 (2.2)  
 Private 397 (10.3) 400 (7.8) 504 (15.0) 3829 (11.4)  
 Uninsured 587 (15.3) 1041 (20.4) 439 (13.0) 7245 (21.5)  
LDL control (mg/dL)** < 0.001
 Not in control (> 129 mg/dL) 512 (13.3) 733 (14.4) 482 (14.3) 5311 (15.8)
 In control (< = 129 mg/dL) 2643 (68.7) 3453 (67.7) 2373 (70.4) 22,888 (68.0)
 Unknown 694 (18.0) 912 (17.9) 515 (15.3) 5439 (16.2)
HbA1c control (%)** < 0.001
 Not in control (> = 7) 2022 (52.5) 2547 (50.0) 1735 (51.5) 17,265 (51.3)
 In control (< 7) 1561 (40.6) 2020 (39.6) 1428 (42.4) 14,186 (42.2)
 Unknown 266 (6.9) 531 (10.4) 207 (6.1) 2187 (6.5)
Blood pressure control (mm Hg)** < 0.001
 Not in control 910 (23.6) 1,174 (23.0) 702 (20.8) 8258 (24.5)
 In control (< 140/90:< 60 yo, < 150/90:> = 60 yo) 2939 (76.4) 3923 (77.0) 2668 (79.2) 25,355 (75.4)
 Unknown - - 1 (0.0) - - 25 (0.1)
  1. *Assessed at most recent office visit prior to snapshot date **Most recent record available prior to snapshot date. P values from chi-square test for general association
  2. ACE/ARB angiotensin-converting-enzyme inhibitor/Angiotensin II receptor blockers, CHC community health center, FPL Federal Poverty Level, HbA1c Hemoglobin A1c, LDL Low-density lipoprotein